Locations:
SearchAdvertisement
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant
Offers a new option for patients 60 and older with relapsed/refractory disease
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression
Advertisement
Advertisement